…or really just one great one: Xconomy needs your help. We’re busy cranking out terrific tech and life sciences journalism and putting on stellar events across the six cities in our network, and we’re looking for a kick-ass marketing coordinator to... Read more »
You wouldn’t throw a fancy dinner party in a 7-Eleven. You wouldn’t hold a symphony concert in a subway station, or teach a meditation class on a tilt-a-whirl ride.
So why does anyone expect readers to read long articles on the Web?
Call me a traitor to my kind,... Read more »
When it comes to tech startups—especially in Internet software and app development—San Diego has been adrift in the horse latitudes. That’s the term Spanish mariners had for the waters where the trade winds died out for days and even weeks at... Read more »
News of FDA drug approvals shone the spotlight on some New England biotechs this week.
—Waltham, MA-based Alkermes (NASDAQ: ALKS) and San Diego-based Amylin Pharmaceuticals(NASDAQ: AMLN) won FDA approval for their injectable diabetes drug exenatide once-weekly (Bydureon). This was... Read more »
Much like the New York Giants charging onto the football field, companies such as bitly, BarkBox, and Gilt Groupe—along with their backers—have upped the caliber of innovation expected from startups in New York. In response to this upswell of activity,... Read more »
Don’t know about you, but I’m less interested in Facebook’s IPO than I am in the efforts of people trying to find the next Facebook out of Boston/Cambridge. One such effort is the new Experiment Fund, based at Harvard University, which... Read more »
At Xconomy’s event yesterday, New York’s Venture Emergence, members of Gilt Groupe’s founding team fascinated a standing-room-only audience with the tale of how, in just four years, they grew from a scrappy startup to one of the most successful e-commerce sites on the... Read more »